Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [Expression profiling]

·发布 2015年1月30日 ·更新 2015年2月8日

样本数

实验数

芯片平台

实验描述

Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2 signaling pathway, and the molecular mechanisms related to treatment response were sought. To search for response predictors, genomic and transcriptomic profiling, PIK3CA mutations and PTEN status were associated to the drug responses and several genes involved in the response of the compounds were identified. RNA from thirteen HER2 positive breast cancer cell lines was isolated and hybridized on Affymetrix arrays.

芯片平台

A-GEOD-18850

[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array [Version 14]（13 例）

样本属性

cell line

AU565, BT474, EFM-192A, HCC1419, HCC1569, HCC1954, HCC202, JIMT1, KPL4, MDA-MB-453, SKBR3, SUM190PT, SUM225

organism

Homo sapiens

sex

female

实验信息

登记号

E-GEOD-58700

GEO 编号

GSE58700

实验类型

transcription profiling by array

物种

Homo sapiens

发布日期

2015年1月30日

更新日期

2015年2月8日

提交者

Henrik Edgren、 Sandra Jernström、 Gunhild M Mælandsmo、 Kristine K Sahlberg、 Sandra Jernström、 Vesa Hongisto、 Olli Kallioniemi、 Eldri U Due、 Suvi-Katri Leivonen、 Anne-Lise Børresen-Dale、 Dagim S Tadele、 Merja Perälä

外部链接

ArrayExpress 原始页 NCBI GEO：GSE58700

分析服务

Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [Expression profiling]

联系地址

微信公众号